Carle Foundation Hospital is a 433-bed regional care hospital in Urbana, Illinois, United States, that has achieved Magnet designation. It is owned by the not-for-profit Carle Foundation, which also consists of Carle Physician Group and Health Alliance Medical Plans. It is the area's only level 1 trauma center.

There are 433 beds in The Carle Foundation Hospital.

During the past decade, The Carle Foundation Hospital conducted 249 clinical trials. In the 10-year time frame, 249 clinical trials started and 110 clinical trials were completed, i.e. on average, 44.2% percent of trials that started reached the finish line to date. In the past 5 years, 102 clinical trials started and 84 clinical trials were completed. i.e. 82.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Carle Foundation Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 119 trials, followed by "Alliance for Clinical Trials in Oncology" with 38 trials sponsored, "SWOG Cancer Research Network" with 38 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 26 trials sponsored and "NRG Oncology" with 26 trials sponsored. Other sponsors include 87 different institutions and companies that sponsored additional 59 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Carle Foundation Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 137 trials as a collaborator, "NRG Oncology" with 20 trials as a collaborator, "Canadian Cancer Trials Group" with 10 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator and "NCIC Clinical Trials Group" with 3 trials as a collaborator. Other collaborators include 54 different institutions and companies that were collaborators in the rest 53 trials.

According to Clinical.Site data, the most researched conditions in "The Carle Foundation Hospital" are "Stage IV Lung Cancer AJCC v8" (11 trials), "Invasive Breast Carcinoma" (9 trials), "Recurrent Lung Non-Small Cell Carcinoma" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials) and "Recurrent Ovarian Carcinoma" (8 trials). Many other conditions were trialed in "The Carle Foundation Hospital" in a lesser frequency.

Most popular intervention types in "The Carle Foundation Hospital" are "Drug" (238 trials), "Other" (171 trials), "Biological" (108 trials), "Procedure" (77 trials) and "Radiation" (34 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (69 trials), "Quality-of-Life Assessment" (62 trials), "Questionnaire Administration" (45 trials), "Computed Tomography" (36 trials) and "Biospecimen Collection" (35 trials). Other intervention names were less common.

The vast majority of trials in "The Carle Foundation Hospital" are 273 trials for "All" genders, 47 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "The Carle Foundation Hospital". undefined are not yet recruiting, 96 are recruiting, 122 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 79 completed trials in The Carle Foundation Hospital, 5 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in The Carle Foundation Hospital, 13 "Phase 1" clinical trials were conducted, 146 "Phase 2" clinical trials and 137 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 26 trials that are defined as “Not Applicable".